JP2008520717A - 多発性硬化症についての処置 - Google Patents

多発性硬化症についての処置 Download PDF

Info

Publication number
JP2008520717A
JP2008520717A JP2007543322A JP2007543322A JP2008520717A JP 2008520717 A JP2008520717 A JP 2008520717A JP 2007543322 A JP2007543322 A JP 2007543322A JP 2007543322 A JP2007543322 A JP 2007543322A JP 2008520717 A JP2008520717 A JP 2008520717A
Authority
JP
Japan
Prior art keywords
vla
subject
antibody
agent
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520717A5 (https=
Inventor
マイケル パンザラ，
アルフレッド サンドロック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2008520717A publication Critical patent/JP2008520717A/ja
Publication of JP2008520717A5 publication Critical patent/JP2008520717A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007543322A 2004-11-19 2005-11-18 多発性硬化症についての処置 Pending JP2008520717A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62970004P 2004-11-19 2004-11-19
PCT/US2005/042052 WO2006055871A2 (en) 2004-11-19 2005-11-18 Treatment for multiple sclerosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008294839A Division JP2009091360A (ja) 2004-11-19 2008-11-18 多発性硬化症についての処置
JP2012188532A Division JP2012233009A (ja) 2004-11-19 2012-08-29 多発性硬化症についての処置

Publications (2)

Publication Number Publication Date
JP2008520717A true JP2008520717A (ja) 2008-06-19
JP2008520717A5 JP2008520717A5 (https=) 2009-01-15

Family

ID=36407818

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007543322A Pending JP2008520717A (ja) 2004-11-19 2005-11-18 多発性硬化症についての処置
JP2008294839A Pending JP2009091360A (ja) 2004-11-19 2008-11-18 多発性硬化症についての処置
JP2012188532A Pending JP2012233009A (ja) 2004-11-19 2012-08-29 多発性硬化症についての処置
JP2014247885A Pending JP2015044873A (ja) 2004-11-19 2014-12-08 多発性硬化症についての処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2008294839A Pending JP2009091360A (ja) 2004-11-19 2008-11-18 多発性硬化症についての処置
JP2012188532A Pending JP2012233009A (ja) 2004-11-19 2012-08-29 多発性硬化症についての処置
JP2014247885A Pending JP2015044873A (ja) 2004-11-19 2014-12-08 多発性硬化症についての処置

Country Status (8)

Country Link
US (1) US20090202527A1 (https=)
EP (2) EP1827491A4 (https=)
JP (4) JP2008520717A (https=)
CN (2) CN103169965A (https=)
AU (1) AU2005306399B2 (https=)
CA (1) CA2587597A1 (https=)
HK (1) HK1203055A1 (https=)
WO (1) WO2006055871A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
EP1833509A4 (en) * 2004-12-03 2008-12-03 Biogen Idec Inc DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
CN105658667A (zh) * 2013-07-05 2016-06-08 比奥根Ma公司 用于治疗中风的组合物和方法
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019018688A1 (en) 2017-07-20 2019-01-24 The University Of Virginia Patent Foundation METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
WO2020150214A1 (en) * 2019-01-14 2020-07-23 University Of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503920A (ja) * 1989-09-27 1993-06-24 エラン　ファーマシューテイカルズ　インコーポレイテッド 血液脳関門のモデル
JPH08507680A (ja) * 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
JPH09508272A (ja) * 1994-01-25 1997-08-26 アテナ ニューロサイエンシズ インコーポレイティド 白血球付着分子 ｖｌａ−４に対するヒト化抗体
WO2003072040A2 (en) * 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
JP2007531761A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤およびそれを使用する方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0670735T3 (da) * 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) * 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
JP2001527040A (ja) * 1997-12-30 2001-12-25 バイオアブソーバブル コンセプツ，インコーポレイティド 神経系の脳血管性疾患を治療、抑制及び防止するためのテトラサイクリン及び／又はテトラサイクリン誘導体
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
JP2002538167A (ja) * 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
AU2446801A (en) * 1999-12-23 2001-07-03 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU2001245899B2 (en) * 2000-03-31 2006-06-15 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP1401484A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
CA2860702C (en) * 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040203031A1 (en) * 2002-04-03 2004-10-14 University Of Pennsylvania Methods for determining drug responsiveness
AU2003211063A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
EP3064215A1 (en) * 2002-10-16 2016-09-07 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease
CA2514125A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição
RS52213B (sr) * 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
AU2006254772B2 (en) * 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2007008943A2 (en) * 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503920A (ja) * 1989-09-27 1993-06-24 エラン　ファーマシューテイカルズ　インコーポレイテッド 血液脳関門のモデル
JPH08507680A (ja) * 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
JPH09508272A (ja) * 1994-01-25 1997-08-26 アテナ ニューロサイエンシズ インコーポレイティド 白血球付着分子 ｖｌａ−４に対するヒト化抗体
WO2003072040A2 (en) * 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
JP2007531761A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤およびそれを使用する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011034704; 'ＡＮＴＥＧＲＥＮ　Ｏｎｅ-Ｙｅａｒ　Ｄａｔａ　ｆｒｏｍ　Ｐｈａｓｅ　ＩＩＩ　ＡＦＦＩＲＭ　Ｓｔｕｄｙ　Ｓｈｏｗｅｄ　Ｃｏｍｐｅｌｌｉｎｇ　Ｒｅｓｕｌｔｓ　ｉｎ　Ｍｅｅｔｉｎｇ　Ｐｒｉｍａｒｙ　Ｅｎｄｐ' ［ｏｎｌｉｎｅ］ , 20041108 *
JPN6011034706; ＳＡＮＤＢＯＲＮ，Ｗ．Ｊ．　ｅｔ　ａｌ: 'Ｅｆｆｉｃａｃｙ　ａｓｓｅｓｓｍｅｎｔ　ｏｆ　ｎａｔａｌｉｚｕｍａｂ　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　Ｃｒｏｈｎ'ｓ　ｄｉｓｅａｓｅ　ａｎｄ　ｐｒｉｏｒ　ｈｉｓｔｏｒｙ　ｏｆ　ａｎｔｉ-ＴＮＦ　ｔｈ' Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ Ｖｏｌ．１２６，　Ｎｏ．４, 200404, ｐ．Ａ７６ *
JPN6012010750; 牧山和也　他: '非特異性炎症性腸疾患の診療はどこまで進歩したか　免疫療法の臨床研究の現状' クリニカ Ｖｏｌ．２３，　Ｎｏ．５, 1996, ｐ．３８９-３９３ *
JPN7011002393; Ｅｘｐｅｒｔ　Ｒｅｖｉｅｗ　ｏｆ　Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｖｏｌ．４，　Ｎｏ．４, 200407, ｐ．５７１-５８０ *

Also Published As

Publication number Publication date
CA2587597A1 (en) 2006-05-26
WO2006055871A2 (en) 2006-05-26
EP1827491A2 (en) 2007-09-05
JP2012233009A (ja) 2012-11-29
CN103169965A (zh) 2013-06-26
WO2006055871A3 (en) 2006-08-03
EP1827491A4 (en) 2010-07-14
AU2005306399A1 (en) 2006-05-26
HK1203055A1 (en) 2015-10-16
JP2009091360A (ja) 2009-04-30
CN101102792A (zh) 2008-01-09
US20090202527A1 (en) 2009-08-13
AU2005306399B2 (en) 2012-02-09
JP2015044873A (ja) 2015-03-12
EP2808033A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
US11571477B2 (en) Anti-VLA-4 antibodies
JP2015044873A (ja) 多発性硬化症についての処置
WO2006036371A2 (en) Combination therapy
JP2008520717A5 (https=)
AU2012202575B2 (en) Treatment for Multiple Sclerosis
HK40076026A (en) Anti-vla-4 antibodies
HK40005884A (en) Anti-vla-4 antibodies
HK1186413A (en) Treatment for multiple sclerosis
HK1242339B (en) Anti-vla-4 antibodies
CA2478456A1 (en) Combination therapy
HK1174931A (en) Anti-vla-4 antibodies
HK1174931B (en) Anti-vla-4 antibodies

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130304